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Severe anaphylactic or allergic reactions may occur during blood transfusion 
to patients who are IgA-deficient and have anti-IgA in their blood, particularly 
those with class-specific antibodies. These patients are a particular challenge 
to the hospital transfusion service when large volumes of blood components 
are required for transfusion support, as in liver transplantation. We have 
successfully provided blood components for 3 such patients undergoing liver 
transplantation. Red cells were washed manually or by automated technique. 
Platelets were washed manually. All plasma was from IgA-deficient donors. 
One patient's entire plasma requirements were supplied by autologous plas- 
mapheresis. Serial determinations of IgA levels and anti-IgA titers in 1 patient 
demonstrated an abrupt fall in anti-IgA with the appearance of barely detect- 
able amounts of IgA during the surgery. IgA-containing plasma cells were 
demonstrated in the biopsies of liver homografts of 2 patients following trans- 
plantation. IgA deficiency with anti-IgA can be successfully managed during 
liver transplantation with advance planning. ..................... 
Allergic reactions to blood transfusion are relatively 
common, occurring in approximately 2-3% of recipients 
[l]. Most of these are relatively minor; however, severe 
allergic reactions, including anaphylaxis, occur with an 
estimated frequency of 1 : 20,000-1 : 47,000 transfusions 
[2]. One group of patients who appear to be at  significant- 
ly increased risk of severe reactions are those with anti- 
body to IgA. Such antibodies are considered as class-spe- 
cific when they react with all human IgA myeloma pro- 
teins and are defined as limited specificity when they react 
with some, but not all, examples of IgA [3]. Most serious 
transfusion reactions in this setting have been associated 
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with class-specific antibodies, although reactions may oc- 
cur with limited specificity antibodies as well [2, 41. 
Liver transplantation often requires large volumes of 
plasma containing blood components for patient support. 
When patients who are IgA-deficient, with anti-IgA, be- 
come candidates for liver transplantation, the hospital 
transfusion service is faced with a significant challenge to 
provide safe blood components in a timely fashion. There 
are currently no published guidelines on how to approach 
the transfusion management of such patients. We have 
successfully supported 3 patients with IgA deficiency and 
anti-IgA during liver transplantation. 
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Table 1. Clinical patient data prior to - 
Patient Age1 Prior transfusions IgA level Anti-Iga Diagnosis 
---. n..,n:f:n;t.r transplant 
RBC plasma reactions bCX 
1 48/F none none none 0.015 gA limited primary 
2 
3 32lM 5 units 2 units yes' 0.05 g/l class hepatitis C 
biliary cirrhosis 
hepatitis 
16/F none 2units none <0.01 s/l class autoimmune 
' Nausea, vomiting, diarrhea, later fever and chills. 
Materials and Methods Table 2. Perioperative transfusion management 
IgA levels were determined by passive hemagglutination. Anti- 
IgA levels were determined by hemagglutination inhibition as de- 
scribed [ 5 ] .  Red blood cells (RBC) and platelets were washed by 
manual or automated technique using Cobe 2991 Cell Washers. 
Patient Number of units transfused 
1 2 3 
Preoperative 
RBC 0 0 7 h  
Case Reports 
Intraoperative 
RBC 6 h  6' 26 
FFP 6" 8 d  32 * 
The patients were (1) a 48-year-old woman with primary biliary platelets 0 6 b  24 
cirrhosis, (2) a 16-year-old woman with autoimmune chronic active postoperative 
hepatitis, and (3) a 32-year-old man with chronic hepatitis C. Pa- RBC 2 b  0 2b 
tients 1 and 2 were transplanted at University Hospital, London, FFP 4a 4* 0 
Ontario. Patient 3 was transplanted at The University of Michigan 
Hospitals, Ann Arbor, Mich. 
The transfusion history and IgA status of each patient is shown in 
table 1. All were IgA-deficient. The first 2 were identified byquantita- 
tive immunoglobulin determination during pretransplantation eval- 
uation. Patient 1 had not been transfused but had been pregnant and 
had an antibody of limited specificity. The antibody in patient 2 was 
discovered after transfusion of plasma without any clinical reaction, 
which was most likely the mode of sensitization. Patient 3 had been 
transfused with 5 units of RBC 3 years before without experiencing 
any transfusion reaction. However, during pretransplant evaluation 
he received plasma and experienced a prompt allergic reaction. A 
class-specific antibody was then detected in his serum 
The perioperative transfusion management of eachpatient issum- 
marizedin table 2. Patient lhadcoagulationparametersinthenormal 
range. Six 500-ml units of autologous plasma were collected by aphe- 
resis and frozen. This patient received 8 units of washed RBC, and 
10 units of autologous fresh frozen plasma (FFP, expressed as 200-ml 
equivalents). Patient 2 received 6 units of washed RBC and a pool of 
6 random donor platelets, washed by manual technique, as well as 
12 units of FFP from IgA deficient donors. Patient 3 received 7 units 
of RBC 5 weeks before transplant because of gastrointestinal hemor- 
rhage. These were washed by automated technique. Intraoperative- 
ly, he received 24 units of RBC, washed by automated technique, 
4 pools of 6 random donor platelet concentrates, washed by manual 
technique, and 32 units of IgA-defencient FFP. At the end of the 
operation, he also received 2 units of red blood cells, adenine-saline 
a Autologous, expressed as FFP equivalents (200 ml). 
Washed. 
Twenty-four units washed, manualof automated, last2 units AS-1 
and not washed. 
IgA-deficient. 
added (AS-1) that were not washed, as the supply of washed RBCwas 
exhausted. Postoperatively, he received 2 additional units washed 
RBC. 
The results of successive IgA levels and anti-IgA titer in the 
perioperative period of patient 3 are shown in figure 1. Before the 
transplant procedure, the patient had a high titer of anti-IgA that 
dropped precipitously during the operation to undetectable levels, as 
the result of dilution by crystalloid solutions and non-IgA-containing 
blood components. At the end of the procedure, both IgA (0.06 gll) 
and anti-IgA (titer: 1 : 10) were present in the serum at the lowest limit 
of detectability, and persisted over the subsequent 2 weeks. The pa- 
tient also received 65 gof intravenous immunoglobulin (Sandoglobu- 
lin) postoperatively as passive immunotherapy for cytomegalovirus 
prophylaxis, and another 30-gram dose as an outpatient. Ten months 
after transplantation, this patient had no detectable IgA and anti-IgA 
titer of 1:1,280. He had not received blood products in the interim. 
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All 3 patients were successfully transplanted without any evi- 
dence of adverse reactions to transfusion. Patient l died of heart 
disease unrelated to any transfusion sequelae 5 years after trans- 
plantation. Patients 2 and 3 were alive 11 and 13 months posttrans- 
plant, respectively. Posttransplant liver biopsies from patients 2 and 3 
were available for review. In order to determine if there was evidence 
of donor lymphocyte engraftment and IgA production, sections were 
stained by immunoperoxidase technique for IgA. In both cases, IgA- 
containing plasma cells were readily identified in portal tracts. 
Discussion 
The experience gained from these 3 cases demon- 
strates that, with advance planning, a history of IgA defi- 
ciency with anti-IgA is not a contraindication to elective 
surgical procedures requiring large-volume blood product 
support, such as liver transplantation, even if the patient 
has manifested previous severe allergic reactions to blood 
transfusion. As serial determinations of antibody titer in 
patient 3 demonstrates, there is a progressive and marked 
reduction in anti-IgA levels as the volume of transfused 
blood components increases. In this case, the antibody 
reached undetectable levels after approximately a 2 blood 
volume transfusion. Subsequently, the transfusion of rou- 
tinely collected RBC, or other plasma-containing compo- 
nents, appears to be of little risk during the period when 
the anti-IgA levels are very low. In addition, since Sando- 
globulin contains a relatively large amount of IgA com- 
pared to other immunoglobulin concentrates (562k53 ygl 
ml) [6] it appears that subsequent challenge with IgA 
while the titer of antibody is low poses no additional risk of 
reaction. 
Clearly, autologous blood transfusion is preferable for 
these patients, if possible. When this is not an option, 
IgA-deficient FFP and cellular blood components are 
preferable, but the latter is not practical in liver trans- 
plantation as the availability of a suitable organ donor 
cannot be predicted. However, our experience indicates 
that routinely washed red blood cells and platelets can be 
safely used for transfusion support. All of the units we 
processed by either manual or automated technique were 
washed in unbuffered saline. Recently, a technique for 
washing platelets, which removes a greater proportion of 
IgA, using citrate-buffered saline, has been published [7]. 
While such a technique has theoretical advantages, it may 
not be necessary in all cases. 
As part of the transplantation immunosuppression 
protocol, all of our patients received preoperative ste- 
roids, which may have ameliorated any potential allergic 
reactions. Although there is no incontrovertible evidence 
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Fig. 1. Perioperative changes in IgA levels (m) and anti-IgA titer 
(0) in patient 3. RBCW = washed RBC; PPW = washed platelet 
pool; FFP = IgA-deficient fresh frozen plasma; RBC-AS = AS-1 red 
blood cells. 
that pretransfusion steroid administration will prevent 
anaphylaxis, it seems prudent that prophylactic steroids 
should be considered when non-IgA-deficient compo- 
nents are transfused. 
Finally, the presence of IgA in the graft poses little, if 
any, risk to the patient. IgA-secreting plasma cells can be 
demonstrated in homografts after transplantation. Their 
presence may serve as a marker of donor lymphocyte en- 
graftment. 
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